Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan in Eosinophilic Esophagitis (EoE)
NCT06851559Phase 2Active, not recruiting
- Sponsor
- Phathom Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Vonoprazan 20 mg with Placebo (2 arms). Primary endpoint: Peak Esophageal Intraepithelial Eosinophil Count <15 eos/hpf at 12 weeks. Started Oct 2025; status: active, not recruiting.
02
Drugs
vonoprazan
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT06851559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851559.